J. Mendelsohn

900 total citations
19 papers, 686 citations indexed

About

J. Mendelsohn is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, J. Mendelsohn has authored 19 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in J. Mendelsohn's work include Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (4 papers) and Glycosylation and Glycoproteins Research (2 papers). J. Mendelsohn is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (4 papers) and Glycosylation and Glycoproteins Research (2 papers). J. Mendelsohn collaborates with scholars based in United States, Netherlands and Israel. J. Mendelsohn's co-authors include Hideo Masui, Rakesh Kumar, Andrew D. Seidman, Christopher C. Benz, I. Craig Henderson, Debu Tripathy, Nancy T. Sklarin, Paul Peter Rosen, José Baselga and J. Moore and has published in prestigious journals such as Nature, Journal of Biological Chemistry and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. Mendelsohn

16 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Mendelsohn United States 10 373 266 251 164 100 19 686
A Harłozińska Poland 14 219 0.6× 234 0.9× 103 0.4× 67 0.4× 83 0.8× 55 587
Barbara Tomasovic United States 11 283 0.8× 239 0.9× 99 0.4× 68 0.4× 49 0.5× 20 621
K. Aogi Japan 13 535 1.4× 153 0.6× 185 0.7× 131 0.8× 56 0.6× 33 770
M. Koukourakis Greece 12 227 0.6× 284 1.1× 96 0.4× 125 0.8× 46 0.5× 28 563
Aikseng Ooi Japan 10 276 0.7× 327 1.2× 117 0.5× 210 1.3× 161 1.6× 18 654
Carlo Gatti Italy 14 383 1.0× 551 2.1× 102 0.4× 112 0.7× 115 1.1× 30 896
Tetsuji Sawada Japan 20 392 1.1× 494 1.9× 89 0.4× 138 0.8× 117 1.2× 38 928
Enzo Mammano Italy 18 414 1.1× 470 1.8× 113 0.5× 173 1.1× 183 1.8× 31 1.0k
Andrea Milani Italy 12 416 1.1× 268 1.0× 81 0.3× 208 1.3× 67 0.7× 35 765
Vincent J. Bakanauskas United States 8 428 1.1× 685 2.6× 117 0.5× 230 1.4× 58 0.6× 8 975

Countries citing papers authored by J. Mendelsohn

Since Specialization
Citations

This map shows the geographic impact of J. Mendelsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mendelsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mendelsohn more than expected).

Fields of papers citing papers by J. Mendelsohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mendelsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mendelsohn. The network helps show where J. Mendelsohn may publish in the future.

Co-authorship network of co-authors of J. Mendelsohn

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mendelsohn. A scholar is included among the top collaborators of J. Mendelsohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mendelsohn. J. Mendelsohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Baselga, José, Debu Tripathy, J. Mendelsohn, et al.. (1999). Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.. PubMed. 26(4 Suppl 12). 78–83. 229 indexed citations
2.
Ciardiello, Fortunato, Roberto Bianco, V. Damiano, et al.. (1999). Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer. European Journal of Cancer. 35. S103–S103.
3.
Slovin, Susan F., P O Livingston, Neal Rosen, et al.. (1996). Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.. PubMed. 23(6 Suppl 14). 41–8. 15 indexed citations
4.
Kumar, Rakesh & J. Mendelsohn. (1994). Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.. PubMed. 14(3A). 1001–8. 3 indexed citations
5.
Fan, Zhen, J. Mendelsohn, Hideo Masui, & Rakesh Kumar. (1993). Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies.. Journal of Biological Chemistry. 268(28). 21073–21079. 32 indexed citations
6.
Mendelsohn, J., et al.. (1992). Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.. PubMed. 52(12). 3335–9. 83 indexed citations
7.
Goldenberg, Alec, et al.. (1989). Imaging of Human Tumor Xenografts With an Indium-111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody. JNCI Journal of the National Cancer Institute. 81(21). 1616–1625. 81 indexed citations
8.
Masui, Hideo, et al.. (1989). Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.. PubMed. 49(13). 3482–8. 46 indexed citations
9.
Sauvage, Carol A., J. Mendelsohn, Jayne Lesley, & Ian S. Trowbridge. (1987). Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.. PubMed. 47(3). 747–53. 34 indexed citations
10.
Hoyt, David B., et al.. (1986). Resuscitation with Fluosol-DA 20%???Tolerance to Sepsis. The Journal of Trauma: Injury, Infection, and Critical Care. 26(8). 713–717. 1 indexed citations
11.
Hounsell, E F, Irit Lax, Richard Kris, et al.. (1985). The carbohydrate specificities of the monoclonal antibodies 29.1, 445 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Bioscience Reports. 5(1). 83–94. 36 indexed citations
12.
Young, James A., Robert O. Dillman, Stephen L. Seagren, et al.. (1982). Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung.. PubMed. 66(6). 1399–401. 6 indexed citations
13.
Mendelsohn, J., et al.. (1982). Characterization and drug treatment of human lymphocytes in a colony assay. 1. 1 indexed citations
14.
Hudig, Dorothy, et al.. (1981). Effects of unsaturated fatty acids and ethanol on human lymphocyte natural cytotoxicity (NK). Federation Proceedings. 40. 1 indexed citations
15.
Mendelsohn, J., et al.. (1981). Modulation of cytosine arabinoside triphosphate (ara-CTP) and trinucleotide pools in a human acute leukemia cell line (HL-60) by thymidine (dThd) and hydroxyurea (HU). Proceedings of the American Association for Cancer Research. 22. 2 indexed citations
16.
Vries, J E de, J. Mendelsohn, & W.S. Bont. (1980). Requirement for monocytes in the spontaneous cytotoxic effects of human lymphocytes against non-lymphoid target cells. Nature. 283(5747). 574–576. 12 indexed citations
17.
Byfield, J.E., Rita Barone, J. Mendelsohn, et al.. (1980). Infusional 5-fluorouracil and x-ray therapy for non-resectable esophageal cancer. Cancer. 45(4). 703–708. 94 indexed citations
18.
Taetle, Raymond & J. Mendelsohn. (1980). Modulation of normal and abnormal myeloid progenitor proliferation by cyclic nucleotides and PGE1.. PubMed. 6(4). 701–18. 8 indexed citations
19.
Taetle, Raymond, J. Mendelsohn, & Stephen B. Howell. (1979). Nucleoside requirements for the protection of human marrow from methotrexate (MTX). Proceedings of the American Association for Cancer Research. 20. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Harłozińska Breakdown of academic impact, for papers by Barbara Tomasovic Breakdown of academic impact, for papers by K. Aogi Breakdown of academic impact, for papers by M. Koukourakis Breakdown of academic impact, for papers by Aikseng Ooi Breakdown of academic impact, for papers by Carlo Gatti Breakdown of academic impact, for papers by Tetsuji Sawada Breakdown of academic impact, for papers by Enzo Mammano Breakdown of academic impact, for papers by Andrea Milani Breakdown of academic impact, for papers by Vincent J. Bakanauskas
Rankless by CCL
2026